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Abstract
Mouse models of cancer represent powerful tools for analysing the role of genetic alterations in carcinogenesis.
Using a mouse model that allows tamoxifen-inducible somatic activation (by Cre-mediated recombination) of
oncogenic K-rasG12D in a wide range of tissues, we observed hyperplasia of squamous epithelium located in moist
or frequently abraded mucosa, with the most dramatic effects in the oral mucosa. This epithelium showed a
sequence of squamous hyperplasia followed by squamous papilloma with dysplasia, in which some areas progressed
to early invasive squamous cell carcinoma, within 14 days of widespread oncogenic K-ras activation. The marked
proliferative response of the oral mucosa to K-rasG12D was most evident in the basal layers of the squamous
epithelium of the outer lip with hair follicles and wet mucosal surface, with these cells staining positively for pAKT
and cyclin D1, showing Ras/AKT pathway activation and increased proliferation with Ki-67 and EdU positivity. The
stromal cells also showed gene activation by recombination and immunopositivity for pERK indicating K-Ras/ERK
pathway activation, but without Ki-67 positivity or increase in stromal proliferation. The oral neoplasms showed
changes in the expression pattern of cytokeratins (CK6 and CK13), similar to those observed in human oral
tumours. Sporadic activation of the K-rasG12D allele (due to background spontaneous recombination in occasional
cells) resulted in the development of benign oral squamous papillomas only showing a mild degree of dysplasia
with no invasion. In summary, we show that oral mucosa is acutely sensitive to oncogenic K-ras, as widespread
expression of activated K-ras in the murine oral mucosal squamous epithelium and underlying stroma can drive
the oral squamous papilloma–carcinoma sequence.
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Introduction
Ras genes are some of the most widely studied cancer-
related genes, due to their frequent activation in human
tumours [1]. These small GTPases act as molecu-
lar switches that transfer information from the mem-
brane to the nucleus. Ras proteins interact with mul-
tiple downstream effector pathways, the best studied
of which are those involved in mitogenic signalling,
such as the RAF/MEK/ERK pathway, and survival,
such as the phosphoinositol-3 kinase (PI3K)/PDK/AKT
pathway [2]. Among ras oncogenes, K-ras is the
most frequently activated in human tumours, with mis-
sense mutations at codons 12, 13, and 61 resulting
in decreased GTPase activity and constitutive sig-
nalling [3]. Although in some countries, such as India,
the prevalence of K-RAS mutations in oral squa-
mous cell carcinomas is as high as 50%, due to
environmental factors, in Western countries such as
the UK the prevalence is much lower, ∼5% [4–6].
Following analysis of micro-RNA expression patterns
in human oral squamous cell carcinomas (OSCC),
Shin et al [6] concluded that miR-181a functions as
an OSCC suppressor by targeting the K-RAS onco-
gene, suppressing expression of mutant K-RAS in
OSCC cell lines and inhibiting their growth in cul-
ture, indicating the importance of mutated K-RAS
as a driver mutation for OSCC growth. However, it
remains to be established how mutated K-ras con-
tributes to oral carcinogenesis in this small proportion
of cases.
Unveiling the role of oncogenic K-ras in the devel-
opment of human cancer has been greatly aided
by the ability to manipulate the mouse genome in
order to develop tumour models of sporadic K-ras
activation, which closely recapitulate those events
responsible for human disease [7–14]. Indeed, the
Jackson et al allele (LSL-K-rasG12D) [8] has been
widely used to identify the effects of oncogenic
K-ras in specific tissues, including the oral cavity
Copyright  2011 Pathological Society of Great Britain and Ireland. J Pathol 2011; 224: 22–32
Published by John Wiley & Sons, Ltd. www.pathsoc.org.uk www.thejournalofpathology.com
Oncogenic K-ras in the oral mucosa 23
[15], lung and GI tract [16], the haematopoietic sys-
tem, [17,18] and pancreas [16,19,20]. This has been
achieved by breeding LSL-K-rasG12D mice with mouse
lines that express Cre from tissue-specific inducible
promoters.
In the present study, we bred LSL-K-rasG12D mice
with a mouse line carrying an inducible Cre recom-
binase (RosaCreERT 2). Administration of tamoxifen
to these mice results in somatic expression of onco-
genic K-ras in a wide variety of tissues. We observed
hyperplasia of moist or frequently abraded squa-
mous mucosa, with the most dramatic effects seen
in the oral cavity: squamous papillomas showing
dysplasia with areas of focal invasion (squamous
cell carcinoma). Alternatively, sporadic expression of
the K-rasG12D allele (due to spontaneous recombi-
nation) only resulted in the development of squa-
mous papillomas with mild dysplasia, following a
long latency. Thus, we show the acute sensitivity of
the oral mucosa to oncogenic K-ras in oral tumour
development.
Materials and methods
Mice and dosing regimes
Mice were housed in accordance with Home Office
regulations (UK) and fed a diet of mouse pellets
and water ad libitum. Mice carrying the Lox-stop-
Lox (LSL)-K-rasG12D allele [8] were kindly provided
by David Tuveson (Cancer Research Institute, Cam-
bridge, UK). Mice carrying the tamoxifen-inducible
Cre knocked into the Rosa locus (RosaCreERT 2) [21]
and mice carrying a floxed LacZ reporter gene with
an internal stop codon knocked into the Rosa locus
(RosaR26R) [22] were kindly provided by Jos Jonkers
(Netherlands Cancer Institute, Amsterdam, The Nether-
lands). All mice were on a mixed 129/Sv-C57BL/6J
background. To achieve somatic expression of onco-
genic K-ras, 8-week-old mice carrying both the Lox-
stop-Lox (LSL)-K-rasG12D and RosaCreERT 2 alleles
(LSL-K-ras+/G12D; RosaCreERT 2/CreERT 2; hereafter
termed K-ras+/G12D) and wild-type littermate con-
trols (LSL-K-ras+/+; RosaCreERT 2/CreERT 2; hereafter
termed K-ras+/+) were given a single intraperitoneal
dose of tamoxifen (4-OHT; Tamoxifen Free Base,
MP Biomedicals, Cleveland, OH, USA) dissolved
in sterile sunflower oil. Some mice were also left
‘untreated’ to assess spontaneous levels of tumour
development (due to ‘leaky’ Cre expression from
the RosaCreERT 2 allele). For 5-ethynyl-2′-deoxyuridine
(EdU) experiments, mice were dosed intraperitoneally
with 0.5 mg of EdU (Invitrogen, Paisley, UK) dis-
solved in phosphate-buffered saline (pH 7.5) 1 week
after tamoxifen treatment and sacrificed 16 h later. For
all studies, the mice were examined twice daily for
signs of morbidity, at which time they were sacrificed
(if not done so earlier) and a full necropsy was per-
formed.
Genotyping
Genotyping for the LSL-K-rasG12D [8], RosaCreERT 2
[21], and RosaR26R [22] alleles was performed as
described previously. Excision of the stop cassette from
the LSL-K-rasG12D allele in tamoxifen-dosed mice
was determined using PCR amplification with primers
KrasSLRec3A: 5′-GCA GCT AAT GGC TCT CAA
AGG-3′ and KrasSLRec3B: 5′-TTG GCT CCA ACA
CAG ATG TTC-3′ (62 ◦C annealing temperature for
5 cycles, followed by 60 ◦C for 30 cycles). The PCR
products were resolved in a 3% agarose gel with the
wild-type and activated K-rasG12D alleles generating
a 196 bp and a 240 bp band, respectively.
Reverse transcription (RT)-PCR and restriction
fragment length polymorphism (RFLP) analysis
Total RNA (1.5 µg) isolated from oral tissue using
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) was
treated with Turbo Dnase (Ambion, Austin, TX, USA)
and reverse-transcribed using the BD Sprint Kit with
random hexamers (BD Clontech, Mountain View, CA,
USA), according to the manufacturers’ instructions.
The cDNA was then subjected to PCR and RFLP
analysis to distinguish between the wild-type and
mutant K-ras alleles, as previously described [15].
Histological analysis
All tissues and tumours were fixed in 10% neutral-
buffered formalin (NBF) at room temperature over-
night. Samples were then transferred to 75% ethanol,
embedded in paraffin, sectioned, and stained with
haematoxylin and eosin (H&E).
Immunofluorescence, immunohistochemistry, and
β-gal staining
Immunofluorescence analysis was performed on tis-
sue samples that had been embedded and frozen in
OCT compound at −70 ◦C. Sections were probed with
anti-phospho-ERK 1/2, anti-phospho-AKT (#9106 and
#4058, Cell Signalling Technology, New England Bio-
Labs, Hertfordshire, UK), and anti-cyclin D1 (RM-
9104, Neomarkers, Thermo Scientific, Cheshire, UK).
Following incubation with primary antibodies, positive
cells were visualized with Alexa Fluor 488-conjugated
goat anti-rabbit antibodies for phospho-AKT and cyclin
D1, and Alexa Fluor 547-conjugated goat anti-mouse
antibodies for phospho-ERK (Invitrogen).
Whole mounts of lip and oral epithelium were pre-
pared as described previously [23]. EdU incorpora-
tion was detected with a Click chemistry kit (Invit-
rogen) according to the manufacturer’s instructions.
Digital images were captured using confocal micro-
scopes (Zeiss LSM 510 META and NIKON Eclipse
TE2000-U).
Immunohistochemical analysis was performed on
formalin-fixed, paraffin-embedded tissue sections using
either rabbit polyclonal anti-β galactosidase anti-
body (Abcam, Cambridge, UK), rabbit polyclonal
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anti-cytokeratin 6 (Abcam), rabbit monoclonal anti-
cytokeratin 13 (EPR3671; Abcam) or rat anti-mouse
Ki-67 (Dako UK Ltd, Ely, UK). Immunohistochemical
signal was detected by secondary biotinylated don-
key anti-rabbit antibody (Stratech Scientific, Suffolk,
UK), followed by a Vector ABC tertiary kit (Vector
Laboratories, Burlingame, CA, USA) according to the
manufacturer’s instructions. All immunohistochemistry
was performed on a BondMax machine (Vision Biosys-
tems, Newcastle, UK), according to the manufacturer’s
instructions, by the Human Research Tissue Bank at
Addenbrooke’s Hospital (Cambridge, UK).
The raw array CGH data may be found at ftp://ftp.
sanger.ac.uk/pub/da1/KRAS_lvdw.
Results
Hyperplasia and neoplasia of the oral mucosa in
response to expression of K-rasG12D
K-ras+/G12D mice were given a single intraperi-
toneal dose of 1 mg of tamoxifen at 8 weeks of
age, resulting in activation of the oncogenic K-
rasG12D, as demonstrated by PCR analysis on DNA
extracted from a wide range of tissues 1 week after
induction (Figure 1A). Within 14 days of dosing, a
marked hyperproliferative phenotype was observed in
the oral cavity of K-ras+/G12D mice, but not K-
ras+/+ mice (Figures 1B and 1C). At this time-point,
the study was terminated and the mice were sac-
rificed as they had become progressively malnour-
ished from an inability to feed or drink. Histolog-
ical analysis of the oral mucosa from these mice
showed squamous hyperplasia (Figure 1D), papilloma
formation with mild–moderate dysplasia (Figure 1E),
and areas of early invasive squamous cell carcinoma
(Figure 1F), often with combinations of adjacent squa-
mous hyperplasia, dysplastic papilloma, and focal inva-
sion. The total penetrance of this phenotype (25/25
mice), together with the rapid development of the
oral tumours, suggests that few additional mutations
or epigenetic changes are required for mutant K-
ras-induced oral squamous hyperplasia and papilloma
formation with neoplasia, supported by CGH analy-
sis of tumours from these mice revealing no gross
genomic instability (Supporting information, Supple-
mentary Figure 1).
Molecular analysis of oral lesions by RT-PCR and
RFLP confirmed that the mutant (activated) K-rasG12D
allele was being expressed (Figure 1G). In the absence
of an antibody specific for the activated form of
K-ras, we used Rosa26 reporter (Rosa+/R26R) mice
as a surrogate marker for Cre-mediated activation
of K-ras, as these mice carry a loxP-flanked STOP
cassette that prevents expression of a lacZ gene;
however, when crossed with a mouse line carry-
ing Cre recombinase, the STOP cassette is removed
and lacZ is expressed in the cells/tissues where Cre
is expressed [22]. Immunohistochemical analysis of
β-galactosidase expression in the oral mucosa of K-
ras+/G12D; Rosa+/CreERT 2; Rosa+/R26R mice dosed
with 1 mg of tamoxifen at 8 weeks of age showed
oral squamous hyperplasia, papilloma formation, and
dysplastic papilloma (with irregular basal aspect) with
strong β-galactosidase expression in stromal cells as
well as in the squamous epithelium (Figures 1H and 1I
and Supporting information, Supplementary Figure 2).
This shows that there is widespread Cre recombi-
nase activity in the oral mucosa of tamoxifen-treated
mice carrying the RosaCreERT 2 allele and thus implies
widespread expression of oncogenic K-rasG12D in the
oral mucosa.
Widespread hyperplastic changes in multiple tissues
in response to expression of K-rasG12D
At the time of sacrifice (2 weeks post-tamoxifen
administration), the K-rasG12D-expressing mice also
showed hyperplastic changes in many other tissues
containing moist or frequently abraded squamous
mucosa, and occasionally other epithelia, both squa-
mous (anal canal, forestomach, vagina, cervix, paw
skin pads) and non-squamous (ovary, endometrium)
(Supporting information, Supplementary Figure 3). In
addition, hyperplasia was noted in haematopoietic
organs (bone marrow, spleen, and liver). However,
the lungs showed multiple adenocarcinomas (Support-
ing information, Supplementary Figure 3). This hyper-
proliferative and neoplastic phenotype was observed
in all the mice examined (n = 10), although the
relative degree of involvement of each of the tis-
sues varied from mouse to mouse. No other tis-
sues histologically examined (pancreas, kidney, blad-
der, testes, small intestine, colon, caecum, oesoph-
agus, thymus, heart, salivary gland, brain, eye, ear,
and tongue) showed any evidence of hyperplasia or
neoplasia. No hyperproliferation of any tissues was
observed in tamoxifen-dosed wild-type littermates (K-
ras+/+ mice; n = 4 mice sacrificed 31 days after
dosing).
Hyperplasia of the oral mucosa occurs in the
squamous epithelium of the mucosal surface, hair
follicles, and sebaceous glands
To examine more closely the marked proliferative
response of the oral mucosa to oncogenic K-ras,
we treated K-ras+/G12D mice with 1 mg of tamox-
ifen (or vehicle) and then 1 week later treated the
mice with 0.5 mg of EdU to mark S-phase cells.
The mice were sacrificed and tissue samples col-
lected 16 h after EdU dosing. At this time-point,
the lips and oral mucosa appeared macroscopically
indistinguishable from vehicle-dosed littermates (‘con-
trols’); however, whole-mount preparation of the lips
and oral mucosa showed marked hyperplasia com-
pared with the lips and oral mucosa from con-
trol animals (Figures 2A–2F). Microscopic exami-
nation of the hair-bearing external epithelium of
the outer lip (Figures 2A and 2D), wet oral mucosa
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Figure 1. Somatic activation of the K -rasG12D allele in mice. (A) PCR analysis of genomic DNA to detect excision of the ‘stop’ cassette in
K -ras+/G12D mice 1 week after being dosed with vehicle or 1 mg of tamoxifen. The wild-type allele generates a 196 bp product, whereas the
activated K -rasG12D allele generates a 240 bp product. The negative control was tail gDNA from a K -ras+/+ mouse and the positive control
was oral tumour gDNA from a K -ras+/G12D mouse. (B, C) Gross appearance of oral tumours that developed in K -ras+/G12D mice 14 days
after being dosed intraperitoneally with 1 mg of tamoxifen. (D–F) Histological analysis of the oral mucosa following haematoxylin and
eosin staining showed squamous hyperplasia (D, see arrow; original magnification ×100), squamous papilloma with dysplasia (E, original
magnification ×25), and early invasive squamous cell carcinoma (F, original magnification ×400). All sections shown are representative.
(G) RNA expression of wild-type and mutant K -ras (K -rasG12D) in lip tissue of mice 14 days after being dosed intraperitoneally with
1 mg of tamoxifen or vehicle. Total RNA was isolated from oral tissue and tumours and reverse-transcribed. The resulting cDNA was
PCR-amplified and subjected to HindIII digestion as previously described [8]. The 448 bp PCR product is digested to generate 300 and 148
bp fragments in the mutant but not the wild-type PCR (as the mutant K -rasG12D allele contains a HindIII restriction site engineered in
exon 1, which is absent in the wild-type allele). (H, I) Immunohistochemical analysis of β-galactosidase expression in the oral cavity of in
K -ras+/G12D; Rosa+/CreERT 2; Rosa+/Rosa26R mice dosed with 1 mg of tamoxifen at 8 weeks of age (H, ×25 and I, ×50 original magnification,
respectively).
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Figure 2. Hyperproliferation of the oral squamous epithelium in K -rasG12D-expressing mice. (A–F) Whole-mount images. K -ras+/G12D
mice were dosed intraperitoneally with vehicle (upper panel images) or 1 mg of tamoxifen (lower panel images) and then 1 week later
dosed with 0.5 mg of EdU before being sacrificed for tissue collection 16 h later. Confocal image Z stack projections of lip whole-mounts
show the outer lip (A, D), mucosa (C, F), and interface space between them (B, E). The whole mounts were stained for EdU (green) and
DAPI (blue). (G–L) Immunofluorescence images. K -ras+/G12D mice were dosed intraperitoneally with vehicle (upper panels) or 1 mg of
tamoxifen (lower panels) and sacrificed 7 days later. Lip cryosections were stained for (G, J) pAKT 473 (green), pERK 1/2 T202/Y204 (red),
and DAPI (blue); (H, K) pAKT 473 (green); and (I, L) cyclin D1 (green). D = dermis; E = epidermis; HF = hair follicle. White arrows and
brackets indicate the thickness of the epithelium, and red arrows and brackets show the thickness of the hair follicle epithelium. Scale
bar = 50 µm.
(Figures 2C and F), and interface between them
(Figures 2B and 2E) revealed the hyperproliferative
phenotype to be in the surface mucosal epithelium,
hair follicles, and sebaceous glands, as shown by
the high percentage of EdU-positive cells in these
areas.
Hyperplasia of the squamous epithelium in the oral
mucosa signals via the pAKT pathway
Several Ras effector pathways, including the Raf/MEK/
ERK (MAPK) and PI3K/AKT kinase cascades, pro-
mote cell proliferation, differentiation, and survival
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Figure 3. Keratin and proliferation staining in the oral epithelium of dosed K -rasG12 mice. Oral epithelium (lips) were immunostained
for cytokeratin 13 (A–D), cytokeratin 6 (E–H), or Ki-67 (I–L) in K -ras+/G12D mice dosed either with vehicle (A, E, I, J) or with 1 mg of
tamoxifen (B–D, F–H, K, L) and collected 14 days later. Original magnification: ×25 (B, C, F); ×100 (A); ×200 (I, K); ×400 (A inset, C
inset, D, E, G, H, J, L).
[24]. To establish the mechanism(s) by which acti-
vated K-ras could be causing hyperproliferation in
the oral mucosa, we stained cryosections from 1 mg
tamoxifen-dosed K-ras+/G12D mice and vehicle-dosed
controls (1 week after dosing) with antibodies to
known downstream targets of Ras signalling, specif-
ically phosphorylated AKT (pAKT) and Erk (pERK)
(Figures 2G–2L). pAKT was detected in the hair fol-
licles and basal layers of surface squamous epithelium
in both induced and vehicle-treated mice (Figures 2G
and 2J). However, the undosed mice showed positive
staining in 1–3 layers of cells (Figure 2H), whereas
in the dosed mice pAKT was typically detectable in
3–6 layers of cells in the epithelium (Figure 2K), with
little positivity in the stromal cells. In contrast, pERK
staining was mainly observed in the stromal cells of
the dermis and not in the squamous epithelium of the
surface or the hair follicles (Figures 2G and 2J). In
corroboration that this oral cavity hyperproliferation is
taking place downstream of K-ras signalling, the hair
follicles and basal layers of the squamous epithelium
also strongly immunostained for cyclin D1 expression
(Figures 2I and 2L) and the proliferation markers EdU
and Ki-67 (Figures 2, 3K, and 3L).
Although the most impressive immunofluorescent
evidence for increased pAKT signalling occurred in
the hair-bearing skin of the outer lip, overall there
is evidence of altered proliferation (increased EdU
and Ki-67 staining) with cyclin D1 expression in
the squamous epithelium of the wet oral mucosa,
which is the cell type giving rise to the hyperpla-
sia–papilloma–dysplasia–carcinoma sequence in this
model. Thus, pAKT seems to be more active in mutant
K-ras-expressing squamous epithelium, probably con-
tributing to the hyperproliferative phenotype. Indeed,
increased expression of pAKT has been reported in
ameloblastic tumours (a benign odontogenic neoplasm
which can undergo malignant transformation) [25] and
benign neoplasms of the salivary gland (pleomorphic
adenomas and myoepitheliomas) [26].
Hyperplastic and neoplastic epithelium shows
evidence of aberrant differentiation
The oral squamous epithelium is a self-renewing tis-
sue with terminal differentiation, involving changes
in the expression of cytokeratins, which can be
studied as major differentiation markers of strati-
fied epithelia. Cytokeratins have also been associ-
ated with different stages of tumour progression in
human oral tumours [27,28]. To determine whether
the oral tumours that developed 14 days after 1 mg
tamoxifen treatment of K-ras+/G12D mice exhibited
changes in the differentiation patterns, we examined
the expression patterns of key cytokeratins expressed
in oral epithelia. Specifically, we studied cytokeratin
13 (CK13), found consistently in the suprabasal lay-
ers of normal squamous epithelia of the oral cavity
with decreased/absent expression in squamous cell dys-
plasia/carcinoma [29–31], and cytokeratin 6 (CK6),
not normally expressed above the basal layer of nor-
mal squamous epithelium, but rapidly induced in
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suprabasal (post-mitotic) cells during conditions of
hyperproliferation [32]. We found that CK13 expres-
sion was decreased from full thickness expression in
normal oral squamous epithelium (Figure 3A) to only
a few superficial cell layers of expression in oral
papillomas (Figure 3B), and to only the most dif-
ferentiated parts (the superficial or upper epithelium)
of hyperplastic and dysplastic squamous epithelium
(Figure 3C).
There was no detectable CK13 expression in the
invasive tongues and clusters of squamous cell car-
cinoma (Figure 3D). In contrast, CK6 expression was
broadened from the basal and first suprabasal layers
seen in normal oral squamous epithelium (Figure 3E)
to almost all cell layers in oral papillomas (Figure 3F),
and there was expression throughout the full thickness
of the hyperplastic and dysplastic squamous epithe-
lium (Figure 3G). High expression was also found in
invasive tongues and clusters in the squamous cell car-
cinoma (Figure 3H). These changes were found in all
tamoxifen-dosed K-ras+/G12D mice (n = 7), but not
in tamoxifen-dosed K-ras+/+ (n = 5) or vehicle-dosed
K-ras+/G12D (n = 5) control mice. Similar changes in
cytokeratin expression patterns were reported in the
oral tumours (benign squamous papillomas) from LSL-
K-rasG12D; K5.Cre∗PR1 mice dosed with RU486 in
the oral cavity [15], and have been observed in human
oral neoplasms [27], suggesting that changes in differ-
entiation markers in the oral tumours that developed in
K-ras+/G12D mice resemble those observed in human
patients.
In addition, in keeping with the EdU results from
mice collected 7 days after exposure to tamoxifen
(Figures 2A–2F), oral mucosa from tamoxifen-dosed
K-Ras+/G12D mice collected 14 days after dosing
showed an increased number of squamous epithelial
cells in several suprabasal layers staining positively
for the cell proliferation marker Ki-67 (Figures 3K
and 3L), but no stromal cell positivity, compared with
vehicle-dosed controls that showed only basal layer
epithelial positivity (Figures 3I and 3J).
Effects of using low doses of tamoxifen
When lower doses of tamoxifen were administered
(1–10 µg), to activate oncogenic K-ras in fewer cells,
thymic lymphomas (Figure 4A) and pulmonary adeno-
carcinomas (Figure 4B) were observed in 100% of the
K-ras+/G12D mice within 14–40 weeks post-treatment
(7/7 of 10 µg-dosed mice and 5/5 of 1 µg-dosed mice)
but never in the tamoxifen-treated K-ras+/+ controls
(0/10). One mouse treated with low-dose tamoxifen,
however, developed a macroscopic ‘outgrowth’ on the
lip/oral mucosa, which histopathologically presented as
a squamous papilloma with only a mild degree of dys-
plasia and no evidence of invasion, with no adjacent
hyperplasia of the surrounding squamous epithelium
(Figure 4C).
Similarly, sporadic activation of K-rasG12D (due to
the RosaCreERT 2 allele producing low levels of back-
ground recombination in the absence of the inducer
[21]) resulted in decreased survival of untreated K-
ras+/G12D mice (Figure 4D), with mice presenting
with pulmonary adenocarcinomas (33/33 cases, 100%)
and leukaemia/lymphoma (27/33 cases, 81%). In addi-
tion, some mice (8/33, 24%) also developed macro-
scopic ‘outgrowths’ on their lips and oral mucosa
(Figure 4E). These were similar to the lesion shown
in Figure 4C, appearing as a single papillomatous out-
growth with only a mild degree of dysplasia and
no adjacent hyperplasia of the surrounding squamous
epithelium (Figure 4F), and were markedly different
to the large areas of hyperplasia and papillomas with
dysplasia (with some areas of focal invasion) seen in
the K-ras+/G12D mice dosed with 1 mg of tamoxifen
(Figures 1B–1E). In addition, some mice also showed
variable degrees of proliferation in the anal squamous
epithelium (9/33, 27%), with the most severe cases
presenting with anal prolapse. In contrast, mice car-
rying wild-type alleles at the K-ras locus (K-ras+/+
mice) never developed tissue hyperplasia or tumours
(12/12 mice) within 12 months. These results sug-
gest that acute expression of K-rasG12D throughout
the abraded and wet mucosal squamous epithelium
has a profound field effect on these tissues that dif-
fers from the phenotype observed when isolated cells
or clones of cells stochastically express K-rasG12D .
Interestingly, array comparative genome hybridization
(aCGH) analysis of oral tissue from the spontaneously
developed tumours (papillomas; n = 3) did not show
any more genomic instability than that of the induced
tumours (n = 5) (Supporting information, Supplemen-
tary Figure 1).
PCR amplification of genomic DNA from sponta-
neously developed tumours in these K-ras+/G12D mice
showed the presence of the recombined K-ras+/G12D
allele (Figure 4G). Interestingly, however, some tis-
sues, such as the liver, showed the presence of the
recombined K-rasG12D allele but no histopatholog-
ical abnormality (Figure 4G). Conversely, some tis-
sues, such as the pancreas, did not show the presence
of the activated K-rasG12D allele (Figure 4G), which
explains why tumours were never observed in this tis-
sue [33].
Discussion
Oral cancer has a high mortality and morbidity, with
a 5-year survival rate for patients of ∼50% [34]. This
high lethality is ascribed to the advanced state of malig-
nancy at the time of detection, as when detected early
they can be cured in 80–90% of cases. Thus, under-
standing the molecular mechanisms involved in ini-
tiation and progression to malignancy of oral cancer
may help earlier detection to improve the prognosis
of the disease and the development of novel thera-
peutic strategies. Around 5% of human oral cancers
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Figure 4. The effect of low Cre expression. Histological analysis of haematoxylin and eosin-stained tissues from K -ras+/G12D mice dosed
intraperitoneally with 1–10 µg of tamoxifen, including (A) a thymic lymphoma (original magnification ×400), (B) multiple adenocarcinomas
of the lung (original magnification ×25), and (C) a lip squamous papilloma with dysplasia (original magnification ×25). (D) Survival of
undosed K -ras+/+ and K -ras+/G12D mice. The median survival for K -ras+/G12D mice was 18–20 weeks. Log-rank (Mantel–Cox) test:
p > 0.0001. (E) Representative example of the gross appearance of oral tumours that ‘spontaneously’ developed in undosed K -ras+/G12D
mice. (F) Histological analysis of haematoxylin and eosin-stained section representative of the ‘spontaneous’ oral papillomas observed
(original magnification ×25). (G) PCR analysis of Cre-mediated removal of the floxed ‘stop’ cassette (and hence expression of the activated
K -rasG12D) on gDNA from selected tissues of K -ras+/G12D mice that spontaneously developed tumours. Mouse 51.1a, which developed a
thymic lymphoma and multiple pulmonary adenocarcinomas, showed activated K -rasG12D in the thymus, lung, and liver. Mouse 29.4e,
which developed an oral papilloma and multiple pulmonary adenocarcinomas, showed activated K -rasG12D in the lip and lung.
have mutated K-ras, but its role as a driver mutation is
uncertain. To this end, we developed a mouse model of
widespread somatic expression of oncogenic K-ras in
the adult mouse by crossing LSL-K-rasG12D mice with
tamoxifen-inducible RosaCreERT 2 mice. Dosing of the
offspring with 1 mg of tamoxifen resulted in the devel-
opment of a marked hyperproliferative and neoplas-
tic phenotype in the oral cavity in K-ras+/G12D mice
(but not K-ras+/+ mice) within 14 days of treatment.
This phenotype involved the lips and oral mucosa,
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showing a sequence of squamous hyperplasia followed
by squamous papilloma with dysplasia, in which some
areas progressed to early invasive squamous cell car-
cinoma (Figure 1). The total penetrance of this pheno-
type, together with the rapid development of the oral
tumours, suggests that few additional mutations or epi-
genetic changes are required for K-ras-induced oral
squamous hyperplasia and dysplastic papilloma forma-
tion in mice. Previous studies have shown that mutant
K-ras expression in mice (using K-ras4bG12D , K-
rasG12D or K-rasV 12 alleles) is sufficient to initiate
lung adenomas and adenocarcinomas [7,9,10], and pan-
creatic tumours [33] with few additional genetic or
epigenetic alterations.
Although our primary interest was in characteriz-
ing the oral hyperproliferative and neoplastic pheno-
type observed in these K-rasG12D-expressing mice,
other hyperplastic and neoplastic pathological abnor-
malities were also observed. Hyperproliferation was
observed in sites of wet or frequently abraded squa-
mous mucosa in addition to the mouth, including
the anus, forestomach, vagina/cervix, and paw skin
pads. Other studies have also recorded the presence
of squamous papillomas in similar tissues (ear and
snout skin, anal and vulvo-vaginal squamous mucosa,
oesophageal and forestomach squamous epithelium
[9,11,18]), as well as lymphoma/leukaemia [9,18], and
lung adenoma/adenocarcinomas [8–11,18] in onco-
genic K-ras-expressing mice. In addition, K-RAS is
one of the most commonly mutated oncogenes in
human lung cancer [35], and oncogenic RAS mutations
have also been detected in haematological malignan-
cies [36,37].
Interestingly, however, some tissues consistently
showed the presence of the activated K-rasG12D allele,
yet never developed any pathological abnormality, such
as the liver, suggesting that expression of oncogenic K-
ras at physiological levels is not sufficient to induce
unscheduled proliferation in certain cell types, and
mutated K-ras does not seem to initiate tumourigenesis
in certain tissue types, as shown in the liver here
and previously [12]. Conversely, some tissues did not
show the presence of the activated K-rasG12D allele,
such as the pancreas, which explains why tumours
of this tissue were never observed despite being seen
in other studies [33] and oncogenic K-RAS being a
known inducer of pancreatic neoplasia (over 90% of
cases of pancreatic cancer show mutations in K-RAS
[38]).
The reason why these animals develop hyperplasia
and neoplasia in the lips and oral mucosa more readily
than in other tissues (apart from the lung) may be partly
due to the fact that the oral squamous mucosa has high
rates of proliferation due to the necessity to maintain a
tissue which is frequently exposed to mild abrasion or
chewing-related trauma. Furthermore, the pre-existing
signalling network status of the oral squamous epithe-
lium may be particularly sensitive to activation of the
K-Ras/PI3K/AKT pathway, making these cells more
prone to tumour development compared with other
tissues. The stromal cells under the oral epithelium
also showed Cre-mediated activation using the β-gal
reporter system, indicating mutant K-ras activation
in these cells as well, corroborated by pERK activa-
tion detected in these cells by immunofluorescence.
Therefore, cross-talk between K-rasG12D-expressing
squamous epithelium and K-rasG12D-expressing adja-
cent stroma may have cooperated to generate rapidly
developing hyperplasia and neoplasia manifested in the
squamous epithlium. Oncogenic K-rasG12D-induced
proliferation in the oral cavity has previously been
reported in two studies. In the first study, ∼30% of
LSL-K-ras+/G12D ; Mx1 +/Cre mice developed squa-
mous papillomas in the oral mucosa [18]. However,
there was no further analysis of these tumours as this
was not relevant to the study. In the second study,
LSL-K-rasG12D ; K5.Cre∗PR1 mice dosed with RU486
in the oral cavity (to induce K-rasG12D expression
under the control of the K5 promoter) developed exo-
phytic papillomas of the oral mucosa, tongue, and
palate 16–24 weeks after exposure [15]. Histologi-
cally, these tumours were classified as benign, showing
marked hyperplasia and up to severe dysplasia, but
with no evidence of invasion into the submucosal tis-
sue.
The phenotype observed by Caulin et al [15] is sim-
ilar to that observed in our sporadic study in which
some of the mice (24%) developed squamous papil-
lomas with only a mild degree of dysplasia, but no
invasion. The isolated nature of these tumours and
the absence of hyperplasia in the surrounding nor-
mal squamous epithelium suggest that these tumours
have originated as a result of clonal expansion of a
single cell expressing an activated K-rasG12D allele.
In contrast, mice with widespread K-rasG12D expres-
sion in the oral mucosal epithelial and stromal cells
showed acute and generalized hyperproliferation of the
oral squamous epithelium that rapidly progressed to
dysplastic papillomas with focal invasion. This raises
the possibility that mutant K-ras expression in a field
of epithelial and stromal cells does not just alter the
behaviour of individual cells, but may have a ‘commu-
nity effect’.
Thus, the data presented here show that tumour
development induced by oncogenic K-rasG12D is
highly dependent on the cell type, with oral squa-
mous epithelium displaying acute sensitivity to onco-
genic K-ras. For the oral cavity, we have shown that
oncogenic K-ras is an important inducer of tumouri-
genesis that functions via the pAKT pathway to initi-
ate squamous hyperplasia, with progression to papil-
loma formation with dysplasia and ultimately inva-
sive squamous carcinoma, producing lesions with dif-
ferentiation characteristics resembling those shown in
human oral neoplasms. Furthermore, if low doses
of tamoxifen are used, or spontaneous recombina-
tion occurs, the development of squamous papillo-
mas with dysplasia after a long latency may allow
the testing of anti-RAS preventative and therapeutic
agents.
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